The company said it will webcast its Annual Meeting of Shareholders live on May 14 at 9 a.m. ET, and that it can be viewed online on the Labcorp Investor Relations website.

8-KRegulation FD DisclosureFiled May 8, 2024Period of report May 8, 2024Summary published (UTC) Oct 27, 2026

Key points

AI summary

The company said it will webcast its Annual Meeting of Shareholders live on May 14 at 9 a.m. ET, and that it can be viewed online on the Labcorp Investor Relations website.
The company said the archived replay of the webcast will be available for 1 year.
The company described itself as a clinical laboratory services company with more than 67,000 employees serving clients in over 100 countries, with diagnostic and drug development laboratory capabilities.
The company said it participated in over 84% of the new drugs approved by the FDA in 2023 and performed more than 600 million tests for patients around the world.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Annual Meeting Webcast Schedule

The company said it will webcast its Annual Meeting of Shareholders live on May 14 at 9 a.m. ET, and that it can be viewed online on the Labcorp Investor Relations website.

Source · Based on the filing body and exhibits

Webcast Replay Availability Period

The company said the archived replay of the webcast will be available for 1 year.

Source · Based on the filing body and exhibits

Company Size and Business Areas

The company described itself as a clinical laboratory services company with more than 67,000 employees serving clients in over 100 countries, with diagnostic and drug development laboratory capabilities.

Source · Based on the filing body and exhibits

Participation in 2023 FDA Drug Approvals and Test Volume

The company said it participated in over 84% of the new drugs approved by the FDA in 2023 and performed more than 600 million tests for patients around the world.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.